Clazakizumab

DRUG10 trials

Sponsors

CSL Behring LLC, CSL Behring, Stanley Jordan, MD, University of North Carolina, Chapel Hill, Cedars-Sinai Medical Center

Conditions

Antibody-mediated RejectionAsthmaAtherosclerotic cardiovascular disease in patients with ESKDCOVID-19COVID-19 InfectionEnd-Stage Renal DiseaseFrailtyInflammation

Phase 1

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

CompletedNCT03380377

Stanley Jordan, MDAntibody-mediated Rejection, Kidney Transplant; Complications, Kidney Transplant Rejection +3

Start: 2018-02-21End: 2024-04-16Updated: 2025-05-06

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Active, not recruitingNCT03380962

Stanley Jordan, MDAntibody-mediated Rejection, End-Stage Renal Disease, Kidney Failure, Chronic +4

Start: 2018-02-27End: 2025-08-30Updated: 2025-03-24

Phase 2

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

CompletedNCT02015520

CSL BehringRheumatoid Arthritis

Start: 2012-06-30End: 2015-06-30Updated: 2021-05-12

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

CompletedNCT04129931

University of North Carolina, Chapel HillAsthma

Start: 2019-12-19End: 2025-03-19Updated: 2026-04-01

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

CompletedNCT04348500

Cedars-Sinai Medical CenterCOVID-19

Start: 2020-04-28End: 2020-09-30Updated: 2024-02-08

Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

TerminatedNCT04381052

Columbia UniversityCOVID-19

Start: 2020-05-18End: 2021-04-01Updated: 2022-04-08

Clazakizumab vs. Placebo - COVID-19 Infection

The Methodist Hospital Research InstituteCOVID-19 Infection

Start: 2020-07-13End: 2021-07-31Target: 60Updated: 2020-07-31

Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study

Active, not recruitingNCT05727384

Anne B. NewmanFrailty, Inflammation

Start: 2023-08-01End: 2026-07-01Updated: 2026-03-04

A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis

RecruitingCTIS2022-500273-14-00

CSL Behring LLCAtherosclerotic cardiovascular disease in patients with ESKD

Start: 2023-07-17Target: 1223Updated: 2026-01-23

Phase 3

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

TerminatedNCT03744910

CSL BehringAntibody-mediated Rejection

Start: 2019-10-14End: 2024-04-08Updated: 2025-07-23

Related Papers

The "Reducing Inflammation for Greater Health Trial (RIGHT)" Study-Concept, Rationale, and Design.

2026-01-10

Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.

2023-11-0913 citations

Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

Trials2022-12-2236 citations

Symptom-driven inhaled corticosteroid/long-acting beta-agonist therapy for adult patients with asthma who are non-adherent to daily maintenance inhalers: a study protocol for a pragmatic randomized controlled trial.

2022-12-054 citations

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10

Transplantation Direct2022-11-1011 citations

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.

2022-09-1519 citations

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

Trials2022-04-0823 citations

Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.

2022-02-0935 citations

Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism

Transplant International2021-06-227 citations

Air quality, Environment and Respiratory Outcomes in Bronchopulmonary Dysplasia, the AERO-BPD cohort study: design and adaptation during the SARS-CoV-2 pandemic

BMJ Open Respiratory Research2021-06-0112 citations

THREE-MONTH RESULTS OF A PHASE 2 TRIAL EVALUATING CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION – EARLY IMPACT OF IL-6 BLOCKADE ON DONOR-SPECIFIC ANTIBODY LEVELS, REJECTION MORPHOLOGY AND GENE EXPRESSION

Transplantation2020-08-28

Antibodies to watch in 2020.

2020-01-01328 citations